Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients have?
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients has 22 citations in the OpenAlex counts ScholarIQ stores.
When was Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients published?
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients has 2017 year in the ScholarIQ index.
What is the open-access status of Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients?
Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients has bronze oa status in the ScholarIQ index.
What is the DOI of Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients?
The DOI for Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients is on the source record.
What is the PMID of Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients?
The PMID for Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients is on the source record.
What is the OpenAlex record for Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients?
The OpenAlex for Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients is on the source record.